Combined compliance, quality and safety software platform can better predict patient-specific risks, deliver population health insights, and proactively improve financial and clinical outcomes
symplr®, the leader in enterprise healthcare operations including governance, risk management, and compliance (“GRC”) SaaS solutions, backed by Clearlake Capital Group, L.P. (together with its affiliates, “Clearlake”) and Charlesbank Capital Partners (together with its affiliates, “Charlesbank”), announced today that it has completed its acquisition of Midas Health Analytics Solutions (“Midas”) from Conduent Incorporated (Nasdaq: CNDT) (“Conduent”).
“The Midas acquisition is complementary with symplr’s existing GRC portfolio, and ensures our customers achieve the clinical, operational, and financial targets necessary for success in the world of value-based care,” said BJ Schaknowski, CEO of symplr. “This acquisition aligns with our mission to provide solutions that support a more efficient and better-serving healthcare system for patients, providers, payers, administrators, and staff of today and tomorrow.”
The addition of the Midas Health Analytics Solutions strengthens symplr’s best-in-class SaaS-based GRC portfolio. Midas bolsters symplr’s ability to improve patient safety and outcomes through its powerful and comprehensive portfolio of patient safety, quality, and advanced analytics software solutions utilized by healthcare organizations across the continuum of care. Midas’ wide-ranging capabilities make incorporating data from diverse information systems easy, assisting in proper reporting, documentation, workflow management, and measurement against years of curated benchmark data.
Healthcare organizations rely on Midas both to analyze clinical utilization and provider practice patterns and to collect outcome-based quality metrics. These performance results are disseminated as actionable insights to all stakeholders. Midas helps healthcare operations teams meet regulatory reporting requirements with The Joint Commission and the Centers for Medicare and Medicaid Services (CMS).
“The addition of Midas presents an exciting opportunity that provides symplr with immense added value to its industry-leading patient safety, quality, and analytics software solutions,” said Behdad Eghbali, Co-Founder and Managing Partner of Clearlake. “symplr is a large-scale software platform with a long, successful track record of integrating acquired solutions into its portfolio to drive better healthcare outcomes for all. We look forward to supporting symplr as it continues executing on its buy-and-build strategy.”
“Midas is a natural complement to symplr’s existing compliance, quality, and safety solutions,” said Ryan Carroll, Managing Director of Charlesbank. “Now, symplr customers can track and trend quality performance over time, proactively manage and mitigate risk, and make data-driven decisions amid constant regulatory change to create a safe care environment.”
The acquisition of Midas represents symplr’s 15th acquisition in the past six years, and its tenth under sponsorship from Clearlake since November 2018. Additionally, in January 2022, Clearlake and symplr announced new and follow-on capital via a Clearlake-managed single asset vehicle fund, providing symplr with access to approximately $1.6 billion in equity capital. Clearlake’s strategic investment enables symplr to continue aggressively pursuing its organic growth initiatives and acquisition strategy, as highlighted by the Midas acquisition.